Moreover, no gene fusions involving CDGs were found in patients with mutations in the oncogenes CTNNB1, DACH1, ERBB2, FGFR3, GNAS, GTF2I, KLF5, KRAS, MSH3, and POLRMT. This suggests that these genes are relatively strong oncogenes that drive cancer development without the need for additional driver gene fusions (Figure S5B). This evidence concerns the gene KRAS and cancer.